Overview:
An increased understanding of the molecular underpinnings of
myelodysplastic syndromes (MDS) has reshaped how the disease is classified and
risk stratified, and new therapies are changing how it is treated. In
lower-risk MDS (LR-MDS), general therapeutics as well as targeted options for
molecularly selected patients have moved the goals of care beyond symptom
control toward disease modification, raising new questions about treatment
selection and sequencing. In higher-risk MDS (HR-MDS), allogeneic hematopoietic
cell transplantation remains the only potentially curative approach and
hypomethylating agent monotherapy remains the standard of care after several
phase 3 trials of HMA-based combinations, did not improve overall survival,
leaving clinicians to interpret a growing body of early-phase data for novel
agents.
This CME-certified Cases and Conversations™ live virtual webcast, held during
the 2026 American Society of Hematology (ASH) Annual Meeting in New Orleans,
will bring together expert faculty to translate the latest evidence into
practical, case-based guidance across the MDS risk spectrum. Through short
didactic presentations, panel discussions of challenging patient cases, and
audience polling and Q&A, the program will cover updated classification and
risk stratification, individualized treatment of LR-MDS and HR-MDS, management
of treatment-related adverse events, and emerging therapies under
investigation, including key data presented at ASH 2026.
Learning Objectives:
Upon completion of this activity, learners will be better able to:
- Establish an accurate diagnosis and risk stratification for patients with MDS to guide treatment planning
- Evaluate recent data and ongoing trials of new and emerging therapies for patients with LR-MDS or HR-MDS
- Develop an individualized treatment plan for patients with LR-MDS or HR-MDS based on disease-related, patient-related, and treatment-related factors
- Proactively monitor, mitigate, and manage adverse events associated with newer therapies for MDS
Target Audience:
This educational activity is directed toward physicians, nurses, NP/PAs, pharmacists, and other HCPs involved in the diagnosis and treatment of MDS.
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.